

**Subject:** Non-Obstetrical Transvaginal Ultrasonography  
**Guideline #:** CG-MED-56  
**Status:** Revised

**Publish Date:** 10/01/2024  
**Last Review Date:** 08/08/2024

## Description

This document addresses the use of non-obstetrical transvaginal ultrasonography for the evaluation of conditions of the pelvis and surrounding tissues.

**Note:** This document does *not* address the use of transvaginal ultrasonography for infertility-related conditions and treatments.

## Clinical Indications

### Medically Necessary:

- A. Non-obstetrical transvaginal ultrasonography is considered **medically necessary** to evaluate or guide treatment for **any** of the following conditions:
1. Abnormal uterine or vaginal bleeding; **or**
  2. Amenorrhea, delayed menses, or dysmenorrhea; **or**
  3. Congenital uterine or lower genital tract anomalies; **or**
  4. Endometriomas or endometriosis, including deeply infiltrating endometriosis of the rectum or rectovaginal septum; **or**
  5. Excessive bleeding, pain, or signs of infection after pelvic surgery; **or**
  6. Follow-up of a previously detected abnormality of the pelvis or surrounding tissues; **or**
  7. Incontinence or pelvic organ prolapse; **or**
  8. New onset of symptoms such as abdominal or pelvic pain, bloating, early satiety, or urinary frequency and urgency, **and** an abnormal abdominal or pelvic examination is suspicious for gynecologic cancers; **or**
  9. Pelvic infection or pelvic inflammatory disease (such as, tubo-ovarian abscess, hydrosalpinx, or pyosalpinx); **or**
  10. Pelvic masses, benign or malignant (such as, adenomyosis, fibroids, cancers of the ovaries, vagina, uterus, or other pelvic structures); **or**
  11. Polycystic ovarian syndrome.
- B. Non-obstetrical transvaginal ultrasonography is considered **medically necessary** to monitor for endometrial or ovarian cancer in individuals with hereditary breast and ovarian cancer syndromes (HBOC), Lynch syndrome, **or** Peutz-Jeghers syndrome.

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

## Non-Obstetrical Transvaginal Ultrasonography

- C. Non-obstetrical transvaginal ultrasonography is considered **medically necessary** to confirm the position of an intrauterine contraceptive device if the device string is not visible **or** there is a suspicion that the device is incorrectly positioned within the uterus.

### Not Medically Necessary:

Transvaginal ultrasonography is considered **not medically necessary** when criteria are not met.

### Coding

*The following codes for treatments and procedures applicable to this guideline are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.*

### When services may be Medically Necessary when criteria are met:

#### CPT

76830 Transvaginal ultrasound [non-obstetrical]

#### ICD-10 Diagnosis

All diagnoses

### When services are Not Medically Necessary:

For the procedure code listed above when criteria are not met.

### Discussion/General Information

Transvaginal ultrasonography (TVU), also referred to as endovaginal ultrasonography, is a pelvic and lower abdominal imaging procedure and type of pelvic ultrasound technique which uses a thin transducer (endocavitary ultrasound probe) covered with acoustic conducting gel and a protective sheath (often plastic or latex) that produces diagnostic anatomic images when introduced through the vaginal canal. While probe placement and manipulation can cause transient discomfort, TVU is typically a painless procedure. TVU allows rapid visualization and detailed images of the pelvic organs including the cervix, fallopian tubes, ovaries, uterus, and vagina and surrounding structures such as the rectum and bladder. No ionizing radiation (x-ray) is involved in TVU imaging. TVU is a widely accepted procedure used in the evaluation of pelvic abnormalities, allowing for medical evaluation of conditions without the need for invasive surgery or techniques that expose individuals to radiation.

In 2014, the American Institute of Ultrasound in Medicine (AIUM) in collaboration with the American College of Radiology (ACR), American College of Obstetricians and Gynecologists (ACOG), the Society of Pediatric Radiology (SPR), and the Society of Radiologists in Ultrasound (SRU) published a revised *Practice Parameter for the Performance of Ultrasound of the Female Pelvis* (AIUM, 2014). This practice parameter provides

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

---

Non-Obstetrical Transvaginal Ultrasonography

---

indications for pelvic ultrasonography, including the transvaginal approach and transabdominal approach. Non-obstetrical indications for TVU include, but are not limited to, evaluation of the following conditions: 1) pelvic pain, pelvic masses, or signs or symptoms of pelvic infection; 2) endocrine abnormalities (including polycystic ovaries); 3) amenorrhea, delayed menses, or dysmenorrhea (painful menses); 4) abnormal vaginal bleeding; 5) congenital uterine and lower genital tract anomalies; 6) postoperative pelvic surgery complications (such as excessive bleeding, pain, or signs of infection); or 7) incontinence or pelvic organ prolapse. Other recommendations for non-obstetrical TVU of the pelvis include: 1) follow-up of a previously detected abnormality; 2) further characterization of a pelvic abnormality noted on another imaging study; 3) guidance for interventional or surgical procedures; 4) localization of an intrauterine contraceptive device; 5) preoperative and postoperative evaluation of pelvic structures; and, 6) screening for malignancy in high-risk individuals.

***Screening for Endometrial Cancer with TVU***

TVU is used as a diagnostic tool to evaluate symptomatic vaginal bleeding by measuring endometrial thickness (ET). In an early systematic review and meta-analysis, Smith-Bindman and colleagues (1998) evaluated 35 studies including 5892 participants to determine the accuracy of TVU in detecting endometrial disease in postmenopausal individuals with vaginal bleeding according to hormone replacement use. TVU was found to have a high sensitivity for detecting endometrial cancer and other endometrial disease. Among individuals with postmenopausal uterine bleeding and cancer, 96% (95% confidence interval [CI], 94%-98%) with cancer had an abnormal ET (> 5 millimeters [mm]) on TVU, while 92% (95% CI, 90%-93%) of the individuals with endometrial disease (cancer, polyp, or atypical hyperplasia) had an abnormal result. In individuals not using hormone replacement therapy, 593 (8%) with normal histological finding had an abnormal TVU result (specificity, 92%; 95% CI, 90%-94%), while 1544 (23%) using hormone replacement therapy had an abnormal TVU result (specificity, 77%; 95% CI, 75%-79%). The probability of cancer in a postmenopausal individual with vaginal bleeding with a 10% pretest probability of endometrial cancer was 1% following a normal TVU result.

Gull and colleagues (2003) used dilation and curettage as a gold standard to evaluate TVU measurement of ET as a predictor of endometrial cancer in individuals reporting postmenopausal bleeding (estrogen-progestin therapy [hormone therapy] and no hormone therapy users). A total of 339 participants were evaluated, of which 39 (11.5%) were diagnosed with endometrial cancer (4 participants had an ET of 5-7 mm and 35 participants had an ET > 8 mm) based on histopathology from curettage. No endometrial cancer was diagnosed in individuals with a recurrent postmenopausal bleeding who had an ET of less than 4 mm at the initial scan. The authors reported 100% sensitivity and 60% specificity of TVU for diagnosing endometrial cancer when using a cutoff point of 4 mm.

An ACOG practice bulletin on endometrial cancer (2015; reaffirmed in 2017) includes a recommendation for use of TVU “when transvaginal ultrasonography is performed for the initial evaluation of patients with postmenopausal bleeding and an endometrial thickness of less than or equal to 4 mm is found, endometrial sampling is not required.” Noting limited or inconsistent scientific evidence, ACOG graded this recommendation as Level B. This recommendation is reiterated in the ACOG committee opinion bulletin on endometrial intraepithelial neoplasia (2015; reaffirmed in 2019), a clinically significant condition that is often a precursor lesion to adenocarcinoma of the endometrium, stating that TVU has excellent negative predictive value (NPV) for

---

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

**Non-Obstetrical Transvaginal Ultrasonography**

---

endometrial cancer in women with postmenopausal bleeding. Likewise, the ACOG practice bulletin on the role of TVU in the evaluation of postmenopausal bleeding (2018) concludes:

- The clinical approach to postmenopausal bleeding requires prompt and efficient evaluation to exclude or diagnose endometrial carcinoma and endometrial intraepithelial neoplasia.
- Transvaginal ultrasonography is appropriate for an initial evaluation of postmenopausal bleeding if the ultrasound images reveal a thin endometrial echo (less than or equal to 4 mm), given that an endometrial thickness of 4 mm or less has a greater than 99% negative predictive value for endometrial cancer.
- Transvaginal ultrasonography is a reasonable alternative to endometrial sampling as a first approach in evaluating a postmenopausal woman with an initial episode of bleeding.
- Transvaginal ultrasonography can be useful in the triage of women in whom office endometrial sampling was performed but tissue was insufficient for diagnosis.

An ACOG practice bulletin on the diagnosis of abnormal uterine bleeding (AUB) in reproductive-aged women (2012; reaffirmed in 2016) states the primary imaging test of the uterus for the evaluation of AUB is TVU. TVU “is useful as a screening test to assess the endometrial cavity for leiomyomas and polyps.” While TVU is helpful for evaluating the myometrium itself, its sensitivity and specificity are lower for evaluating intracavitary pathology (56% and 73%, respectively). Regarding use of TVU in evaluation of AUB in premenopausal women, an ACOG practice bulletin (2015; reaffirmed in 2017) on endometrial cancer states that data is insufficient to support the use of endometrial thickness in the evaluation of AUB in women of reproductive age who are at low risk. “Ultrasound measurement of endometrial thickness in premenopausal women has no diagnostic value and should not be performed.”

For use of TVU in individuals without vaginal bleeding, the National Cancer Institute (NCI) PDQ® for endometrial cancer screening (2022) states that “although TVU can be used to evaluate asymptomatic and occult endometrial pathology, the technique has not been evaluated as a screening method for reducing mortality in asymptomatic women.” The NCI PDQ concludes:

Routine screening of asymptomatic individuals for endometrial cancer has not been evaluated for its impact on endometrial cancer mortality. No studies have evaluated the efficacy of screening with TVU in reducing mortality from endometrial cancer. Although high-risk groups can be identified, the benefit of screening in reducing endometrial cancer mortality in these high-risk groups has not been evaluated. Using the same cutoffs to define an abnormal ET in asymptomatic individuals (Smith-Bindman, 2004) as used in symptomatic individuals (Smith-Bindman, 1998) would result in large numbers of false-positive test results and larger numbers of unnecessary referrals for cytological evaluations. Published recommendations for screening certain groups of individuals at high risk for endometrial cancer are based on opinion regarding presumptive benefit (Burke, 1997).

TVU has been evaluated for use in individuals taking tamoxifen as part of adjuvant therapy for breast cancer and as chemoprevention for women at risk of breast cancer. The effects of tamoxifen may increase the individuals’ risk of developing endometrial pathology, including endometrial polyps, endometrial hyperplasia, and

---

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

---

Non-Obstetrical Transvaginal Ultrasonography

---

endometrial cancer (NCI, 2019). Fung and colleagues (2003) performed a prospective, longitudinal observational study of 304 individuals using tamoxifen over 6 years. Participants underwent annual TVU screening and those with abnormal TVU findings or symptomatic with bleeding underwent endometrial biopsy. A total of 43% of the TVU examinations had associated significant uterine abnormalities identified and required further medical or surgical investigation and treatment. However, most abnormalities (80%) represented benign polyps for which no treatment was needed. A total of 6 cases of primary endometrial cancer were detected, and all of these cases presented with irregular bleeding. The sensitivity of ultrasound was only 63.3%, with a specificity of 60.4%, and a low positive predictive value (PPV) for cancer of only 1%. The investigators concluded that routine sequential TVU in asymptomatic women on tamoxifen "...is not useful because of its low specificity and positive predictive value."

The ACOG committee opinion bulletin on tamoxifen and uterine cancer (2014; reaffirmed in 2021) cites the study by Fung (2003) and two earlier studies and states that "in symptomatic women using tamoxifen, screening for endometrial cancer with routine transvaginal ultrasonography, endometrial biopsy, or both has not been shown to be effective."

### *Screening for Other Endometrial Conditions with TVU*

Adenomyosis occurs when endometrial tissue grows into the muscular wall of the uterus. The displaced endometrial tissue thickens, breaks down, and bleeds during each menstrual cycle. An enlarged uterus and painful, heavy menstrual periods can result. Symptoms often start late in the childbearing years after having children. The cause of adenomyosis remains unknown, but the disease typically disappears after menopause.

Meredith and colleagues (2009) evaluated the accuracy of TVU for diagnosing adenomyosis in individuals undergoing hysterectomy. The presence or absence of adenomyosis was confirmed by histopathologic analysis of hysterectomy specimens. A total of 14 trials with 1895 participants were included in the meta-analysis. The authors reported that TVU predicted adenomyosis with a likelihood ratio of 4.67 (95% CI, 3.13-6.17). The overall prevalence of adenomyosis was 27.9% (95% CI, 25.5-30.3). The probability of adenomyosis with an abnormal TVU was 66.2% (95% CI, 61.6-70.6). The probability of adenomyosis with a normal TVU was 9.1% (95% CI, 7.3-11.1).

Champaneria and colleagues (2010) conducted a systematic review and meta-analysis of individuals with adenomyosis who had a TVU and/or magnetic resonance imaging (MRI) and whose results were compared with a reference standard. A meta-regression was performed to examine how the index tests compared on diagnostic accuracy. A total of 23 articles involving 2312 individuals met the inclusion criteria. TVU had a pooled sensitivity of 72% (95% CI, 65%-79%), specificity of 81% (95% CI, 77%-85%), positive likelihood ratio of 3.7 (95% CI, 2.1-6.4) and negative likelihood ratio of 0.3 (95% CI, 0.1-0.5). MRI had a pooled sensitivity of 77% (95% CI, 67%-85%), specificity of 89% (95% CI, 84%-92%), positive likelihood ratio of 6.5 (95% CI, 4.5-9.3), and negative likelihood ratio of 0.2 (95% CI, 0.1-0.4). The results demonstrated that a correct diagnosis was obtained more often with MRI; however, both TVU and MRI showed high levels of accuracy for the non-invasive diagnosis of adenomyosis.

---

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

---

Non-Obstetrical Transvaginal Ultrasonography

---

The ACOG practice bulletin on the diagnosis of abnormal uterine bleeding in reproductive-aged women (2012, reaffirmed in 2016) states adenomyosis can be diagnosed with TVU in an individual with an abnormal physical examination such as an enlarged or globular uterus on bimanual examination. “Ultrasonographic findings that support a diagnosis of adenomyosis include heterogeneous myometrium, myometrial cysts, asymmetric myometrial thickness, and subendometrial echogenic linear striations.”

A retrospective cohort study of 754 individuals (256 of reproductive age and 498 postmenopausal) evaluated the diagnostic performance of TVU compared to hysteroscopy for evaluation of suspected endometrial pathologies. In the reproductive-age group, for the diagnosis of endometrial disease, TVU had a sensitivity of 96.0%, specificity of 58.0%, PPV of 94.4%, NPV of 66.6%, and accuracy of 91.5%; hysteroscopy had a sensitivity of 91.8%, specificity of 76.6%, PPV of 96.0%, NPV of 60.5%, and accuracy of 89.7%. In the postmenopausal group, TVU had a sensitivity of 99.0%, specificity of 19.0%, PPV of 96.1%, NPV of 50.0%, and accuracy of 95.3%; hysteroscopy had a sensitivity of 96.7%, specificity of 86.9%, PPV of 99.2%, NPV of 58.8%, and accuracy of 96.2%. Authors conclude that TVU demonstrated a comparable diagnostic performance to hysteroscopy for diagnosing endometrial pathologies (Yela, 2018).

A small retrospective study sought to compare the efficacy of magnetic resonance imaging (MRI) and TVU in detecting deep infiltrating endometriosis. A total of 48 women with suspicion of deep infiltrating endometriosis and no previous hysterectomy, bowel resection, or urinary tract surgery were enrolled. The diagnosis made using MRI or TVU was considered positive when it correlated with histology. Sensitivity, specificity and accuracy were calculated. For recto-vaginal and vaginal endometriosis examination, TVU demonstrated greater accuracy than MRI (77% vs 69% and 94% vs 89%, respectively), whereas for bladder endometriosis MRI was superior to TVU (96% vs 92%). The sensitivity and specificity varied widely by the nodule’s suspected anatomical location (recto-vaginal, vaginal, utero-sacral ligaments, recto-sigmoid, bladder, or ureter) This study adds to the body of literature demonstrating the clinical utility of TVU as a diagnostic tool in diagnosing deep infiltrating endometriosis but suggests its accuracy may depend on the suspected location of affected tissue (Hernández, 2019).

A systematic review sought to characterize the value of TVU compared to MRI in the evaluation of adenomyosis. A total of 32 studies were ultimately chosen for inclusion in the analysis (case reports were excluded). While both TVU and MRI demonstrated high sensitivity and specificity, TVU surpassed MRI in terms of sensitivity (0.81 vs 0.71, respectively), while MRI had a higher specificity than TVU (0.91 vs 0.87, respectively). The authors concluded that “this systematic review and meta-analysis demonstrates comparably high accuracy for both TVUS and MRI in the diagnosis of adenomyosis” (Liu, 2021).

### ***Screening for Ovarian Cancer with TVU***

There is substantial evidence in peer-reviewed population-based studies to indicate that routine screening of women at average risk of developing ovarian cancer with annual TVU screening does not result in a decrease in ovarian cancer mortality (NCI, 2022). In a randomized controlled clinical trial of individuals recruited from 13 centers across the United Kingdom from 2001 to 2005 (Ovarian Cancer Screening and Mortality in the UK Collaborative Trial of Ovarian Cancer Screening [UKCTOCS] [NCT00058032]), outcomes among 50,623 postmenopausal individuals aged 50 to 74 years who were randomly assigned to 7 to 11 rounds of annual

---

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

**Non-Obstetrical Transvaginal Ultrasonography**

screening with TVU alone and 50,264 who underwent multimodal screening with cancer antigen (CA)-125 testing and TVU were compared with results of 101,299 individuals who were not screened (the comparison group). The protocol was amended twice after trial initiation, but before the final analysis: 1) the study was extended to achieve greater power, and 2) criteria for referral in the multimodal arm were liberalized to increase the percentage of positive screens (Jacobs, 2016). TVUs were scored as normal, resulting in continued annual screening; intermediate, leading to repeat CA-125 and TVU at 3 months; or abnormal, requiring repeat testing within 6 weeks. In the TVU arm, 314 cancers were diagnosed and 154 ovarian cancer-related deaths occurred compared with the non-screened arm, in which 630 cancers were diagnosed and 347 ovarian cancer-related deaths occurred. Mortality was non-significantly lower with TVU screening (11%; 95% CI, -7% to 27%;  $p=0.21$ ). TVU screening resulted in 50 surgeries per 10,000 women for a false-positive screen. Complications resulted from less than 1% of screens and 3.4% of operations. Over a median of 11.1 years, ovarian cancer deaths occurred among 0.30% of screened women and 0.34% of unscreened women (Jacobs, 2016; Sharma, 2012). The ovarian cancer mortality rate was 3.8 deaths per 10,000 women in the screened group and 3.6 deaths per 10,000 person-years in the usual-care group, yielding a mortality rate ratio of 1.06 (95% CI, 0.87-1.30) (NCI, 2022).

Buys and colleagues (2011) evaluated the effect of screening for ovarian cancer on mortality in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. This clinical trial conducted at 10 screening centers across the United States randomly assigned 78,216 women aged 55 to 74 years to undergo either annual screening ( $n=39,105$ ) or usual care ( $n=39,111$ ). The intervention group was offered annual screening with CA-125 for 6 years and TVU for 4 years. Participants and their health care practitioners received the screening test results and managed evaluation of abnormal results. The usual care group was not offered annual screening with CA-125 for 6 years or TVU but received their usual medical care. Participants were followed up for a maximum of 13 years (median 12.4 years, range 10.9-13.0 years) for cancer diagnoses and death until February 28, 2010. The primary outcome was mortality from ovarian cancer, including primary peritoneal and fallopian tube cancers. Secondary outcomes included ovarian cancer incidence and complications associated with screening examinations and diagnostic procedures. A total of 212 women were diagnosed with ovarian cancer (5.7 per 10,000 person-years) in the intervention group and 176 (4.7 per 10,000 person-years) in the usual care group (rate ratio [RR], 1.21; 95% CI, 0.99-1.48). There were 118 deaths as a result of ovarian cancer (3.1 per 10,000 person-years) in the intervention group and 100 deaths (2.6 per 10,000 person-years) in the usual care group (mortality RR, 1.18; 95% CI, 0.82-1.71). Of 3285 women with false-positive results (approximately 10%), 1080 underwent surgical follow-up; 163 women experienced at least one serious complication (15%). A total of 2924 deaths were attributed to other causes (excluding ovarian, colorectal, and lung cancer) (76.6 per 10,000 person-years) in the intervention group and 2914 deaths (76.2 per 10,000 person-years) in the usual care group (RR, 1.01; 95% CI, 0.96-1.06). The results of this large population-based clinical trial among women in the general U.S. population concluded that simultaneous screening with CA-125 and TVU compared with usual care did not reduce ovarian cancer mortality. The PPV of CA-125 and TVU screening was just greater than 1% across all screening rounds. In addition, diagnostic evaluation following a false-positive screening test result was associated with complications (Buys, 2011; Partridge, 2009).

The current U.S. Preventive Services Task Force (USPSTF, 2018) guidelines for ovarian cancer screening among asymptomatic, average-risk women recommend against screening for ovarian cancer in women, as “there is moderate or high certainty that the service has no net benefit or that harms outweigh the benefits (Grade D: The USPSTF recommends against the service).” This reaffirmation statement indicates the USPSTF found adequate

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

**Non-Obstetrical Transvaginal Ultrasonography**

---

evidence that annual screening with TVU and testing for a serum tumor marker CA-125 in women does not reduce the number of ovarian cancer deaths (Henderson, 2018). This recommendation applies to asymptomatic women; however, women with known genetic mutations that increase their risk for ovarian cancer (for example, BRCA mutations) are not included in this recommendation.

The ACOG Committee on Gynecologic Practice and Society of Gynecologic Oncologists offers the following recommendations and conclusions on the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer in women at average risk (2017), stating:

- Currently, there is no strategy for early detection of ovarian cancer that reduces ovarian cancer mortality.
- The use of transvaginal ultrasonography and tumor markers (such as CA-125), alone or in combination, for the early detection of ovarian cancer in average-risk women have not been proven to reduce mortality, and harms exist from invasive diagnostic testing (eg, surgery) resulting from false-positive test results.

***TVU for Cervical Cancer***

The ACR published their Appropriateness Criteria for the Pretreatment Evaluation and Follow-Up of Invasive Cancer of the Cervix in 2023. In that document the ACR does not support the use of TVU for this indication. They specifically state:

Although TVUS of the pelvis plays an important role in local disease assessment, its limited depth of penetration makes it a poor choice of modality for a complete nodal and metastatic disease assessment. Cross-sectional imaging is preferred.

There is no relevant literature to support the use of pelvic TVUS in the surveillance of patients with cervical cancer.

***TVU in Individuals with Hereditary Breast and Ovarian Cancer Syndrome (including Cowden Syndrome), Lynch Syndrome and Peutz-Jeghers Syndrome******Hereditary Breast and Ovarian Cancer Syndrome***

The National Comprehensive Cancer Network (NCCN) clinical practice guideline (CPG) for genetic/familial high-risk assessment in breast, ovarian, and pancreatic cancer (V3.2024) states:

Transvaginal ultrasound to screen for endometrial cancer in postmenopausal individuals has not been shown to be sufficiently sensitive or specific as to support a positive recommendation, but may be considered at the clinician's discretion. Transvaginal ultrasound is not recommended as a screening tool in premenopausal individuals due to the wide range of endometrial stripe thickness throughout the normal menstrual cycle.

---

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.



**Non-Obstetrical Transvaginal Ultrasonography**

---

Additionally, they state:

Screening with transvaginal ultrasound with or without random endometrial biopsies is done in some settings but its benefit is unclear.

The National Society of Genetic Counselors (NSGC) has published a practice guideline on risk assessment and genetic counseling for hereditary breast and ovarian cancer (Berliner, 2013). Medical management (surveillance) options for high-risk women are as follows:

Although unproven, annual or semiannual transvaginal ultrasound, pelvic exam and testing for serum CA-125 to screen for ovarian cancer beginning at 30 years of age should be considered.

The ACOG practice bulletin on hereditary breast and ovarian cancer syndrome (2017) recommends that risk-reducing salpingo-oophorectomy (RRSO), including removal of the ovaries and fallopian tubes in their entirety, be offered by age 40 years for women with *BRCA1* or *BRCA2* mutations. In addition, the practice bulletin states:

In women with *BRCA* mutations or who have a personal or family history of ovarian cancer, routine ovarian cancer screening with measurement of serum CA-125 level or transvaginal ultrasonography generally is not recommended. Transvaginal ultrasonography or measurement of serum CA-125 level may be reasonable for short-term surveillance in women at high risk of ovarian cancer starting at age 30-35 years until the time they choose to pursue risk-reducing bilateral salpingo-oophorectomy, which is the only intervention to reduce ovarian cancer-specific mortality.

In support of this recommendation, ACOG cites the current NCCN guideline for genetic/familial high-risk assessment in breast and/or ovarian cancer (V3.2023) and outcomes of the phase II United Kingdom Familial Ovarian Cancer Screening Study (UK-FOCSS) (Rosenthal, 2017), the largest trial to date in high-risk women monitored using the risk of ovarian cancer algorithm (ROCA). ROCA is a 2-stage screening strategy that establishes a baseline CA-125 level for each individual. Variation from this baseline indicates additional CA-125 testing and TVU screening. (RRSO was encouraged throughout the study. Participants were observed via cancer registries, questionnaires, and notification by centers. Between June 14, 2007, and May 15, 2012, 4348 participants underwent 13,728 person-years of screening. The median follow-up time was 4.8 years. Cases of cancer that were detected during the screening trial were more often early stage compared with cases of cancer diagnosed more than 1 year after screening ended. A significant number of cancers were identified at risk-reducing surgery. Survival analysis could not be performed. The authors concluded that screening may be an option for women at high risk of ovarian cancer who defer or decline RRSO. Further investigation is necessary to identify better serum markers and improved screening algorithms to improve the positive and negative predictive value of testing. However, it remains unknown whether this strategy would improve survival in screened high-risk women.

### *Lynch Syndrome*

---

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

---

Non-Obstetrical Transvaginal Ultrasonography

---

Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is a rare autosomal dominant inherited cancer susceptibility syndrome that increases the risk of many types of cancer, particularly, cancers of the colon and rectum, collectively referred to as colorectal cancer, and cancers of the endometrium, ovaries, stomach, small intestine, liver, gallbladder duct, upper urinary tract, and brain. Women with Lynch syndrome are at increased risk for endometrial and ovarian cancers, up to 60% for the former. For the latter, risk varies significantly based on affected gene and age (NCCN, V2.2023).

The NCCN CPGs address the use of TVU in the assessment and management of individuals with a genetic/familial high-risk for colorectal cancer (V2.2023) and a genetic/familial high-risk for breast and/or ovarian cancer (V3.2024).

There is no recommendation for use of TVU for screening or surveillance for hereditary colorectal cancer syndrome (NCCN, V2.2023).

Two early studies evaluating TVU and measurement of the endometrial lining for endometrial cancer surveillance in a population of women at high-risk of HNPCC and familial colorectal cancer reported that TVU screening had a high false-positive rate and lacked efficacy (Dove-Edwin, 2002; Rijcken, 2003).

Lecuru (2010) and colleagues assessed the performance of TVU to screen for atypical hyperplasia and endometrial cancer in individuals at risk for Lynch syndrome. Endometrial biopsy was the reference standard. Of 85 individuals with mismatch repair gene mutations or Amsterdam II criteria, 58 had 96 paired ultrasound-biopsy evaluations and were included in the study. TVU or transabdominal ultrasonographic finding was considered normal if no polyps or intrauterine abnormalities were seen and if the maximum endometrial thickness was less than 4 mm in postmenopausal women not receiving hormonal replacement therapy or less than 6 mm in other women. Endometrial biopsy results were categorized as not interpretable, normal, or showing atypical hyperplasia or cancer. Sensitivity, specificity, PPV, NPV, and likelihood ratio of ultrasonography were computed. The median follow-up duration was 51.4 months, with cancer diagnosed in 2 individuals. TVU had 100% sensitivity and 100% NPV, 2.2 positive likelihood ratio, and 0 negative likelihood ratio. No interval cancers occurred.

The ACOG practice bulletin on the clinical management of Lynch syndrome (2014; reaffirmed 2016) states there is no consensus on ovarian cancer surveillance in people with Lynch syndrome. Citing results from the largest gynecologic cancer surveillance study to date (Renkonen-Sinisalo, 2007), neither TVU nor CA-125 testing led to the diagnosis of ovarian cancer in any of the 175 Lynch syndrome mutation carriers screened; therefore, it is unclear whether screening with TVU is effective in people with Lynch syndrome.

The American College of Gastroenterology (ACG) (Syngal, 2015) has published guidelines for the surveillance and management of individuals with hereditary gastrointestinal cancer syndromes, including those addressing the surveillance and management of extracolonic malignancies. For individuals with Lynch syndrome, the recommendations state:

Screening for endometrial cancer (EC) and ovarian cancer should be offered to women at risk for or affected with Lynch syndrome (LS) by endometrial biopsy and transvaginal ultrasound

---

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

---

Non-Obstetrical Transvaginal Ultrasonography

---

annually, starting at age 30 to 35 years before undergoing surgery or if surgery is deferred (conditional recommendations, very low quality of evidence).

*Peutz-Jeghers Syndrome*

Peutz-Jeghers syndrome is a rare autosomal dominant condition characterized by the development of noncancerous growths called hamartomatous polyps in the gastrointestinal tract (particularly the stomach and intestines). Most people with Peutz-Jeghers syndrome develop multiple polyps in the stomach and intestines during childhood or adolescence. Polyps can cause health problems such as recurrent bowel obstructions, chronic bleeding, and abdominal pain. Individuals with Peutz-Jeghers syndrome have an increased risk of developing certain types of cancers (such as, colorectal, pancreas, cervix, ovary, gallbladder, or breast cancer) during their lifetime.

The ACG clinical guideline on genetic testing and management of hereditary gastrointestinal cancer syndromes (Syngal, 2015) states that surveillance for affected or at-risk individuals with Peutz-Jeghers syndrome should include monitoring for colon, stomach, small bowel, pancreas, breast, ovary, uterus, cervix, and testicular cancers. Pelvic exam and pelvic ultrasound or TVU are recommended surveillance procedures for endometrial cancer beginning around 25 years of age (conditional recommendation). For ovarian cancer surveillance, “pelvic exam and pelvic or transvaginal ultrasound, CA-125 are probably not helpful.” No peer-reviewed publications are cited with this recommendation.

***TVU for Evaluation of Adnexal Masses, Abnormal Uterine Bleeding, and Other Pelvic and Gynecologic-Related Conditions****Adnexal Masses*

Adnexal masses (masses of the ovary, fallopian tube, or surrounding tissues) may be detected incidentally on physical examination or at the time of pelvic imaging. Less commonly, a mass may present with symptoms of acute or intermittent pain. TVU has been used with or without other imaging modalities including transrectal ultrasonography (TRUS) and TRUS-guided transrectal biopsy to evaluate the extension of adnexal and pelvic masses, including masses of the cervix, fallopian tube, ovary, retroperitoneum, uterus, or surrounding tissues; and to guide or manage further treatment (such as drainage of deep pelvic and perirectal abscesses) (Giede, 2004; Lorentzen, 2011; Nielsen, 2004; Valentin, 2013a; Valentin, 2013b; Zaritzky, 1979).

The ACOG practice bulletin on the evaluation and management of adnexal masses (2016) states that “although most adnexal masses are benign, the main goal of the diagnostic evaluation is to exclude malignancy.” Based on “good and consistent scientific evidence (Level A),” ACOG provides the following recommendations and conclusions:

- Transvaginal ultrasonography is the recommended imaging modality for a suspected or an incidentally identified pelvic mass. No alternative imaging modality has demonstrated sufficient superiority to transvaginal ultrasonography to justify its routine use.

---

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

# Clinical UM Guideline

## Non-Obstetrical Transvaginal Ultrasonography

---

- Ultrasound findings that should raise the clinician's level of concern regarding malignancy include cyst size greater than 10 cm, papillary or solid components, irregularity, presence of ascites, and high color Doppler flow.

Based on "limited or inconsistent scientific evidence (Level B)," the ACOG practice bulletin (2016) recommends:

- Simple cysts up to 10 cm in diameter on transvaginal ultrasonography performed by experienced ultrasonographers are likely benign and may be safely monitored using repeat imaging without surgical intervention, even in postmenopausal patients.

The ACR published Appropriateness Criteria addressing clinically suspected adnexal masses in 2024. In that document they exhibit support for TVU in these two statements:

Transvaginal US is the most useful initial imaging modality in the assessment of adnexal pathology with a sensitivity > 90%, and diagnostic performance is likely improved when undertaken by experienced operators.

and

The most useful modality for evaluation of adnexal masses includes transvaginal US combined with a transabdominal US approach.

### *Abnormal Uterine Bleeding (AUB)*

The ACOG practice bulletin on endometrial ablation (2007; reaffirmed 2018) refers to the procedure as "...a number of minimally invasive surgical procedures designed to treat AUB in selected women who have no desire for future fertility." Preoperative assessment should include evaluation of structure and histology of the endometrial cavity "...to assess for malignancy or endometrial hyperplasia and to ensure that the length and configuration is suitable for endometrial ablation"; however, "women with endometrial hyperplasia or uterine cancer should not undergo endometrial ablation."

The ACOG practice bulletin on management of AUB associated with ovulatory dysfunction (AUB-O) (2013; reaffirmed 2021) describes the condition as a "spectrum of disorders most commonly associated with heavy, irregular uterine bleeding." TVU is one test that may be used to rule out an anatomic abnormality in order to diagnose a structural cause of AUB-O. The practice bulletin states that traditional methods of endometrial surveillance, including TVU, "...may be compromised after endometrial ablation" in individuals with AUB-O who have completed childbearing. For women with AUB-O who have failed medical management, TVU "...is generally not recommended in the virginal patient." In the premenopausal woman, TVU "...ideally should be scheduled between days 4-6 of the menstrual cycle, when the endometrium is the thinnest."

The American College of Radiology (ACR) Expert Panel on GYN and OB Imaging released their Appropriateness Criteria® for the evaluation of fibroids in 2022. That document provided the following information:

- Clinically suspected fibroids. Initial imaging: US pelvis transvaginal May Be Appropriate

---

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

**Non-Obstetrical Transvaginal Ultrasonography**

- Known fibroids. Treatment planning. Initial imaging: US pelvis transvaginal May Be Appropriate
- Known fibroids. Surveillance or posttreatment imaging. US pelvis transvaginal May Be Appropriate

***TVU for the Evaluation and Management of Endometriosis***

According to the ACOG practice bulletin for management of endometriosis (2010; reaffirmed in 2018), the condition is a gynecologic disorder whose principal symptoms are chronic pain and infertility. The condition occurs in 6% to 10% of women of reproductive age with a greater prevalence in infertile women and women with chronic pelvic pain (38% and 71%-87%, respectively). Clinical manifestations of endometriosis are unpredictable, variable in both presentation and course, and include dysmenorrhea, chronic pelvic pain, dyspareunia, utero-sacral ligament nodularity, and either a symptomatic or asymptomatic adnexal mass.

Guerriero and colleagues (2015) performed a systematic review and meta-analysis to determine the diagnostic accuracy of TVU in the preoperative detection of endometriosis in the uterosacral ligaments (USL), rectovaginal septum (RVS), vagina, and bladder in individuals with clinical suspicion of deep infiltrating endometriosis (DIE). A total of 11 studies (n=1583) were included in the meta-analysis including those by Bazot (2014), Bazot (2009), and Hudelist (2011a). The Guerriero meta-analysis found the following test performance characteristics on pooled analysis:

Pooled Test Characteristics: TVU Detection of Deep Infiltrating Endometriosis (DIE)				
Location	Sensitivity (95% CI)	Specificity (95% CI)	Pretest Probability	Posttest Probability
Uterosacral Ligament (USL)	53% (35% - 70%)	93% (83% - 97%)	54%	90%
Rectovaginal Septum (RVS)	49% (36% - 62%)	98% (95% - 99%)	24%	89%
Vagina	58% (40% - 74%)	96% (87% - 99%)	17%	76%
Bladder	62% (40% - 80%)	100% (97% - 100%)	5%	92%

The authors concluded that the overall diagnostic performance of TVU for detecting DIE in USL, RVS, and the vagina and bladder “is fair with high specificity.”

Xiang 2022 and colleagues conducted a systematic review and meta-analysis on the value of TVU in the diagnosis of deep invasive endometriosis. The review included 12 studies comprised of 1707 study participants. Overall, diagnosis with TVU showed high sensitivity (98%) and specificity (near 100%) in the diagnosis of deep invasive endometriosis.

The ACOG practice bulletin recommendation for the management of endometriosis (2010; reaffirmed in 2018) is based on “good and consistent scientific evidence (Level A),” stating that “imaging studies alone appear to have high predictive accuracy in differentiating an ovarian endometrioma from other adnexal masses, and transvaginal ultrasonography is the imaging modality of choice when assessing the presence of endometriosis.” In addition, TUV “is also the imaging technique of choice to detect the presence of deeply infiltrating endometriosis of the rectum or rectovaginal septum.”

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

## Non-Obstetrical Transvaginal Ultrasonography

In 2024, the ACR published appropriateness criteria for Acute Pelvic Pain in the Reproductive Age Group. That document includes the following statements supporting the use of TVU:

A combined transabdominal and transvaginal approach is typically used for pelvic US imaging, and both should be performed when possible.

TVUS is the most useful method to evaluate the endometrium, early pregnancy, and adnexa. TVUS is currently considered the single best diagnostic modality to assess for ectopic pregnancy.

TVUS and TAUS of the pelvis is the most useful imaging modality for initial assessment when an obstetrical or gynecological etiology is suspected. A combined transabdominal and transvaginal approach is typically used for pelvic US imaging.

There is no relevant literature to support the use of transvaginal pelvic US as the initial imaging modality for clinically suspected nongynecological etiology of pelvic pain in the setting of positive b-hCG. Transabdominal abdominopelvic US would be a preferred modality for assessment. TVUS pelvis may be the appropriate initial imaging approach if pregnancy location and gestational age are unknown at the time of an acute presentation.

There is no relevant literature to support the use of transvaginal pelvic US as the initial imaging modality for clinically suspected nongynecological etiology of pelvic pain in the setting of negative b-hCG. Transabdominal abdominopelvic US would be a preferred modality for assessment.

### *TVU for Confirmation of an Intrauterine Device (IUD)*

De Kroon and colleagues (2003) conducted a prospective study comparing clinical evaluation with TVU measurement of intrauterine device position both immediately following placement and 6 weeks after placement. The primary outcome measures were the PPV and NPV of the clinical evaluation of the IUD position. A total of 195 consecutive women were implanted with an IUD, of which 181 (92.8%) were available for follow-up. Immediately following placement the PPV and NPV of clinical evaluation of IUD position were 0.60 (95% CI, 0.39-0.81) and 0.98 (95% CI, 0.96-1.0), respectively. The prevalence of an abnormal IUD position immediately after placement was 7.7% (95% CI, 3.9-11.4). The PPV and NPV of clinical evaluation at follow-up were 0.54 (95% CI, 0.26-0.81) and 1.0 (95% CI, 0.98 to 1.0), respectively. The prevalence of an abnormal IUD position 6 weeks after placement was 4.0% (95% CI, 1.7 to 7.1). The investigators concluded that the routine use of TVU to monitor the position of an IUD is not indicated as the results of this study show that “without clinical suspicion of an erroneous position, the chances of an inadequately positioned IUD are negligible.”

The ACOG committee opinion bulletin on clinical challenges of long-acting reversible contraceptive methods (2019) states that when IUD strings are not visualized, correct location should be confirmed before the IUD can be relied on for contraception. In these situations where the string is no longer visible, TVU is a viable modality to confirm or reject that the IUD is correctly located in the endometrial cavity.

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

# Clinical UM Guideline

## Non-Obstetrical Transvaginal Ultrasonography

### *Pelvic Floor Dysfunction*

The American College of Radiology (ACR) Expert Panel on GYN and OB Imaging released their Appropriateness Criteria® for the evaluation of pelvic floor dysfunction in females in 2022. That document provided the following information:

- Vaginal protrusion or bulge, or clinically suspected pelvic organ prolapse.  
Initial imaging: US pelvis transvaginal Usually Not Appropriate
- Female Urinary dysfunction (involuntary leakage of urine, or frequent urination, or urgency, or straining to void, or incomplete voiding, or splinting, or digital maneuvers to void).  
Initial imaging: US pelvis transvaginal May Be Appropriate
- Female. Defecatory dysfunction (incontinence of stool or liquid or gas, or straining during defecation, or difficulty initiating defecation, or incomplete evacuation, or splinting or digital maneuvers to defecate).  
Initial imaging: US pelvis transvaginal Usually Not Appropriate
- Female. Follow-up imaging after pelvic floor surgery. Subacute or chronic complications other than recurrent pelvic floor dysfunction.  
Initial imaging: US pelvis transvaginal May Be Appropriate

### *Use of TVU for screening in other populations*

The use of TVU in populations at low risk for the conditions addressed above and in individuals with no symptoms is not recommended by any authoritative organization. The likelihood of finding actionable findings in such populations is low compared to the potential harms including complications from diagnostic procedures for false positive results.

### Definitions

Endocavitary Ultrasound Probe: A long, thin ultrasound acoustic transducer that captures internal diagnostic images when introduced externally into an anatomic space.

Transvaginal: Through the vagina.

### References

#### Peer Reviewed Publications:

1. Alcázar JL, Pérez L, Güell O, et al. Diagnostic performance of transvaginal ultrasound for detecting cervical invasion in women with endometrial carcinoma: A systematic review and meta-analysis. *J Ultrasound Med.* 2019; 38(1):179-189.
2. Allègre L, Callewaert G, Coudray C, et al. Prospective ultrasonographic follow-up of transvaginal lightweight meshes: a 1-year multicenter study. *Int Urogynecol J.* 2021; 32(6):1505-1512.
3. Archer DF, McIntyre-Seltman K, Wilborn WW Jr, et al. Endometrial morphology in asymptomatic postmenopausal women. *Am J Obstet Gynecol.* 1991; 165(2):317-320.

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

**Non-Obstetrical Transvaginal Ultrasonography**

4. Bazot M, Malzy P, Cortez A, et al. Accuracy of transvaginal sonography and rectal endoscopic sonography in the diagnosis of deep infiltrating endometriosis. *Ultrasound Obstet Gynecol.* 2007; 30(7):994-1001.
5. Bazot M, Thomassin I, Hourani R, et al. Diagnostic accuracy of transvaginal sonography for deep pelvic endometriosis. *Ultrasound Obstet Gynecol.* 2004; 24(2):180-185.
6. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. *JAMA.* 2011; 305(22):2295-2303.
7. Champaneria R, Abedin P, Daniels J, et al. Ultrasound scan and magnetic resonance imaging for the diagnosis of adenomyosis: systematic review comparing test accuracy. *Acta Obstet Gynecol Scand.* 2010; 89(11):1374-1384.
8. Cubo-Abert M, Díaz-Feijoo B, Bradbury Met, et al. Diagnostic performance of transvaginal ultrasound and magnetic resonance imaging for preoperative evaluation of low-grade endometrioid endometrial carcinoma: prospective comparative study. *Ultrasound Obstet Gynecol.* 2021; 58(3):469-475.
9. de Kroon CD, van Houwelingen JC, Trimbos JB, Jansen FW. The value of transvaginal ultrasound to monitor the position of an intrauterine device after insertion. A technology assessment study. *Hum Reprod.* 2003; 18(11):2323-2327.
10. Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary non-polyposis colorectal carcinoma and familial colorectal carcinoma. *Cancer.* 2002; 94(6):1708-1712.
11. Egekvist AG, Forman A, Seyer-Hansen M. Transvaginal ultrasonography of rectosigmoid endometriosis: interobserver variation of lesion size. *Acta Obstet Gynecol Scand.* 2012; 91(2):264-268.
12. Farquhar C, Ekeroma A, Furness S, Arroll B. A systematic review of transvaginal ultrasonography, sonohysterography and hysteroscopy for the investigation of abnormal uterine bleeding in premenopausal women. *Acta Obstet Gynecol Scand.* 2003; 82(6):493-504.
13. Fleischer AC, Wheeler JE, Lindsay I, et al. An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms. *Am J Obstet Gynecol.* 2001; 184(2):70-75.
14. Fung MF, Reid A, Faught W, et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. *Gynecol Oncol.* 2003; 91(1):154-159.
15. Gerges B, Li W, Leonardi M, et al. Meta-analysis and systematic review to determine the optimal imaging modality for the detection of bladder deep endometriosis. *Eur J Obstet Gynecol Reprod Biol.* 2021; 261:124-133.
16. Giede C, Toi A, Chapman W, Rosen B. The use of transrectal ultrasound to biopsy pelvic masses in women. *Gynecol Oncol.* 2004; 95(3):552-556.
17. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. *JAMA.* 2004; 291(22):2705-2712.
18. Guerriero S, Ajossa S, Minguez JA, et al. Accuracy of transvaginal ultrasound for diagnosis of deep endometriosis in uterosacral ligaments, rectovaginal septum, vagina and bladder: systematic review and meta-analysis. *Ultrasound Obstet Gynecol.* 2015; 46(5):534-545.
19. Gull B, Karlsson B, Milsom I, Granberg S. Can ultrasound replace dilation and curettage? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer. *Am J Obstet Gynecol.* 2003; 188(2):401-408.

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.



**Non-Obstetrical Transvaginal Ultrasonography**

20. Hernández Gutiérrez A, Spagnolo E, Hidalgo P, et al. Magnetic resonance imaging versus transvaginal ultrasound for complete survey of the pelvic compartments among patients with deep infiltrating endometriosis. *Int J Gynaecol Obstet*. 2019; 146(3):380-385.
21. Hudelist G, Ballard K, English J, et al. Transvaginal sonography vs. clinical examination in the preoperative diagnosis of deep infiltrating endometriosis. *Ultrasound Obstet Gynecol*. 2011a; 37(4):480-487.
22. Hudelist G, English J, Thomas AE, et al. Diagnostic accuracy of transvaginal ultrasound for non-invasive diagnosis of bowel endometriosis: systematic review and meta-analysis. *Ultrasound Obstet Gynecol*. 2011b; 37(3):257-263.
23. Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. *Lancet*. 2016; 387(10022):945-956.
24. Kobayashi H, Yamada Y, Sado T, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. *Int J Gynecol Cancer*. 2008; 18(3):414-420.
25. Langer RD, Pierce JJ, O'Hanlan KA, et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. Postmenopausal Estrogen/Progestin Interventions Trial. *N Engl J Med*. 1997; 337(25):1792-1798.
26. Lecuru F, Huchon C, Metzger U, et al. Contribution of ultrasonography to endometrial cancer screening in patients with hereditary nonpolyposis colorectal cancer/Lynch syndrome. *Int J Gynecol Cancer*. 2010; 20(4):583-587.
27. Leonardi M, Espada M, Choi S, et al. Transvaginal ultrasound can accurately predict the American society of reproductive medicine stage of endometriosis assigned at laparoscopy. *J Minim Invasive Gynecol*. 2020; 27(7):1581-1587.
28. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. *JAMA*. 2006; 296(12):1507-1517.
29. Liu L, Li W, Leonardi M, et al. Diagnostic accuracy of transvaginal ultrasound and magnetic resonance imaging for adenomyosis: systematic review and meta-analysis and review of sonographic diagnostic criteria. *J Ultrasound Med*. 2021;40(11):2289-2306.
30. Liu Z, Sharen G, Wang P, Chen L, Tan L. Clinical and pelvic floor ultrasound characteristics of pelvic organ prolapse recurrence after transvaginal mesh pelvic reconstruction. *BMC Womens Health*. 2022; 22(1):102.
31. Lorentzen T, Nolsoe C, Skjoldbye B. Ultrasound-guided drainage of deep pelvic abscesses: experience with 33 cases. *Ultrasound Med Biol*. 2011; 37(5):723-728.
32. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). *Lancet Oncol*. 2009; 10(4):327-340.
33. Meredith SM, Sanchez-Ramos L, Kaunitz AM. Diagnostic accuracy of transvaginal sonography for the diagnosis of adenomyosis: systematic review and metaanalysis. *Am J Obstet Gynecol*. 2009; 201(1):e101-e106.
34. Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. *Obstet Gynecol*. 2003; 102(3):594-599.
35. Naftalin J, Hoo W, Pateman K, et al. How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic. *Hum Reprod*. 2012; 27(12):3432-3439.
36. Nielsen MB, Torp-Pedersen S. Sonographically guided transrectal or transvaginal one-step catheter placement in deep pelvic and perirectal abscesses. *AJR Am J Roentgenol*. 2004; 183(4):1035-1036.

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

**Non-Obstetrical Transvaginal Ultrasonography**

37. Ozdemir S, Celik C, Gezgin K, et al. Evaluation of endometrial thickness with transvaginal ultrasonography and histopathology in premenopausal women with abnormal vaginal bleeding. *Arch Gynecol Obstet.* 2010; 282(4):395-399.
38. Partridge E, Kreimer AR, Greenlee RT, et al.; PLCO Project Team. Results from four rounds of ovarian cancer screening in a randomized trial. *Obstet Gynecol.* 2009; 113(4):775-782.
39. Reid S, Leonardi M, Lu C, Condous G. The association between ultrasound-based 'soft markers' and endometriosis type/location: A prospective observational study. *Eur J Obstet Gynecol Reprod Biol.* 2019; 234:171-178.
40. Renkonen-Sinisalo L, Butzow R, Leminen A, et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. *Int J Cancer.* 2007; 120(4):821-824.
41. Rijcken FE, Mourits MJ, Kleibeuker JH, et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. *Gynecol Oncol.* 2003; 91(1):74-80.
42. Rosenthal AN, Fraser LSM, Philpott S, et al. Evidence of stage shift in women diagnosed with ovarian cancer during phase II of the United Kingdom Familial Ovarian Cancer Screening Study. *J Clin Oncol.* 2017; 35(13):1411-1420.
43. Savelli L, Manuzzi L, Coe M, et al. Comparison of transvaginal sonography and double-contrast barium enema for diagnosing deep infiltrating endometriosis of the posterior compartment. *Ultrasound Obstet Gynecol.* 2011; 38(4):466-471.
44. Sharma A, Apostolidou S, Burnell M, et al. Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS). *Ultrasound Obstet Gynecol.* 2012; 40(3):338-344.
45. Sharma A, Gentry-Maharaj A, Burnell M, et al. Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study. *BJOG.* 2012; 119(2):207-219.
46. Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. *JAMA.* 1998; 280(17):1510-1517.
47. Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. *Ultrasound Obstet Gynecol.* 2004; 24(5):558-565.
48. Valentin L, Ameye L, Franchi D, et al. Risk of malignancy in unilocular cysts: a study of 1148 adnexal masses classified as unilocular cysts at transvaginal ultrasound and review of the literature. *Ultrasound Obstet Gynecol.* 2013a; 41(1):80-89.
49. Valentin L, Ameye L, Savelli L, et al. Unilocular adnexal cysts with papillary projections but no other solid components: is there a diagnostic method that can classify them reliably as benign or malignant before surgery? *Ultrasound Obstet Gynecol.* 2013b; 41(5):570-581.
50. Valero I, Garcia-Jimenez R, Valdevieso P, et al. Identification of pelvic congestion syndrome using transvaginal ultrasonography. A useful tool. *Tomography.* 2022; 8(1):89-99.
51. van Nagell JR, DePriest PD, Ueland FR, et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. *Cancer.* 2007; 109(9):1887-1896.
52. Xiang Y, Wang G, Zhou L, Wang Q, Yang Q. A systematic review and meta-analysis on transvaginal ultrasonography in the diagnosis of deep invasive endometriosis. *Ann Palliat Med.* 2022; 1(1):281-290.
53. Yela DA, Pini PH, Benetti-Pinto CL. Comparison of endometrial assessment by transvaginal ultrasonography and hysteroscopy. *Int J Gynaecol Obstet.* 2018; 143(1):32-36.

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

**Government Agency, Medical Society, and Other Authoritative Publications:**

1. American College of Obstetricians and Gynecologists (ACOG). Committee on Gynecologic Practice. Committee Opinions. Available at: <https://www.acog.org/clinical/clinical-guidance/committee-opinion>. Accessed on July 25, 2024.
  - Committee Opinion Number 601. Tamoxifen and uterine cancer. June 2014. Reaffirmed 2020.
  - Committee Opinion Number 631. Endometrial intraepithelial neoplasia. May 2015. Reaffirmed 2020.
  - Committee Opinion Number 672. Clinical challenges of long-acting reversible contraceptive methods. Reaffirmed 2020.
  - Committee Opinion Number 716. The role of the obstetrician gynecologist in the early detection of epithelial ovarian cancer in women at average risk. September 2020.
  - Committee Opinion Number 734. The role of transvaginal ultrasonography in the evaluation of postmenopausal bleeding. May 2020.
2. American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins-Gynecology; ACOG Committee on Genetics; Society of Gynecologic Oncologists. ACOG Practice Bulletin No.182: Hereditary breast and ovarian cancer syndrome. 2017; 130(3):e110-e126..
3. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 81: Endometrial ablation. Obstet Gynecol 2007; 109:1233-1248.
4. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 114: Management of endometriosis. Obstet Gynecol. 2010; 116(1):223-236.
5. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 128: Diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol. 2012; 120(1):197-206.
6. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 136: Management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet Gynecol. 2013; 122:176-185.
7. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 174: Evaluation and management of adnexal masses. Obstet Gynecol. 2016; 128(5):e210-e226.
8. American College of Obstetricians and Gynecologists (ACOG). Society of Gynecologic Oncology (SCO). ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet Gynecol. 2014; 124(5):1042-1054.
9. American College of Obstetricians and Gynecologists (ACOG). Society of Gynecologic Oncology (SCO). Practice Bulletin No. 149: Endometrial cancer. Obstet Gynecol. 2015; 125(4):1006-1026.
10. American College of Radiology. Expert Panel on GYN and OB Imaging; Ascher SM, Wasnik AP, Robbins JB, et al. ACR Appropriateness Criteria® Fibroids. J Am Coll Radiol. 2022; 19(11S):S319-S328.
11. American College of Radiology. Expert Panel on GYN and OB Imaging; Brook OR, Dadour JR, Robbins JB, et al. ACR Appropriateness Criteria® Acute Pelvic Pain in the Reproductive Age Group: 2023 Update. J Am Coll Radiol. 2024; 21(6S):S3-S20
12. American College of Radiology. Expert Panel on GYN and OB Imaging; Henrichsen TL, Maturen KE, Robbins JB(3), et al. ACR Appropriateness Criteria® Postmenopausal Acute Pelvic Pain. J Am Coll Radiol. 2021; 18(5S):S119-S125.
13. American College of Radiology. Expert Panel on GYN and OB Imaging; Khatri G, Bhosale PR, Robbins JB, et al. ACR Appropriateness Criteria® Pelvic Floor Dysfunction in Females. J Am Coll Radiol. 2022; 19(5S):S137-S155.

---

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

**Non-Obstetrical Transvaginal Ultrasonography**

14. American College of Radiology. Expert Panel on GYN and OB Imaging; Patel-Lippmann KK, Wasnik AP, Akin EA, et al. ACR Appropriateness Criteria® Clinically Suspected Adnexal Mass, No Acute Symptoms: 2023 Update. J Am Coll Radiol. 2024; 21(6S):S79-S99.
15. American College of Radiology. Expert Panel on GYN and OB Imaging; Robbins JB, Sadowski EA, et al. ACR Appropriateness Criteria® Abnormal Uterine Bleeding. J Am Coll Radiol. 2020; 17:S336-S345.
16. American College of Radiology. Expert Panel on GYN and OB Imaging; Shinagare AB, Burk KS, Kilcoyne A, et al. ACR Appropriateness Criteria® Pretreatment Evaluation and Follow-Up of Invasive Cancer of the Cervix: 2023 Update. J Am Coll Radiol. 2024 ;21(6S):S249-S267.
17. American Institute of Ultrasound in Medicine (AIUM); American College of Radiology (ACR); American College of Obstetricians and Gynecologists (ACOG); Society for Pediatric Radiology (SPR); Society of Radiologists in Ultrasound (SRU). AIUM practice guideline for the performance of ultrasound of the female pelvis. J Ultrasound Med. 2014; 33(6):1122-1130.
18. Berliner JL, Fay AM, Cummings SA, et al. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer. J Genet Couns. 2013; 22(2):155-163.
19. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA. 1997; 277(12):997-1003.
20. Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: an updated evidence review for the U.S. Preventive Services Task Force [Internet]. Rockville, MD: Agency for Healthcare Research and Quality (US); February 2018. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK493399/>. Accessed on July 25, 2024.
21. Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: updated evidence report and systematic review for the U.S. Preventive Services Task Force. JAMA. 2018; 319(6):595-606.
22. NCCN Clinical Practice Guidelines in Oncology®. © 2024 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on July 25, 2024.
  - Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (V3.2024). Revised February 12, 2024
  - Genetic/Familial High-Risk Assessment: Colorectal (V2.2023). Revised October 30, 2023.
  - Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer (V3.2024). Revised July 15, 2024.
23. Syngal S, Brand RE, Church JM, et al; American College of Gastroenterology. ACG clinical guideline. Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015; 110(2):223-262.

**Websites for Additional Information**

1. American Cancer Society (ACS). Cancer Facts and Figures 2023 Available at: <https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2023-cancer-facts-figures.html>. Accessed on July 25, 2024.

**Index**

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

## Non-Obstetrical Transvaginal Ultrasonography

Transvaginal ultrasound  
TVU  
TV-US  
TVUS

**The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.**

### History

Status	Date	Action
Revised	08/08/2024	Medical Policy & Technology Assessment Committee (MPTAC) review. Revised NMN statement. Revised Discussion, References, and Websites sections.
Reviewed	08/10/2023	MPTAC review. Revised Background/Overview, Definitions, References, and Websites for Additional Information sections.
Reviewed	08/11/2022	MPTAC review. Updated Background/Overview, References, and Websites for Additional Information.
Reviewed	08/12/2021	MPTAC review. Updated Background/Overview, References, and Websites for Additional Information.
Reviewed	08/13/2020	MPTAC review. Updated Discussion/General Information, References, and Websites for Additional Information sections. Reformatted Coding section.
Reviewed	08/22/2019	MPTAC review. Updated Discussion/General Information, References, and Websites for Additional Information sections.
Reviewed	11/08/2018	MPTAC review. Updated Discussion/General Information, References, and Websites for Additional Information sections.
Reviewed	01/25/2018	MPTAC review. The document header wording updated from “Current Effective Date” to “Publish Date.” Updated Discussion/General Information, References, and Websites for Additional Information sections.
New	02/02/2017	MPTAC review. Initial document development.

Federal and State law, as well as contract language including definitions and specific coverage provisions/exclusions, and Medical Policy take precedence over Clinical UM Guidelines and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that services are rendered must be used. Clinical UM Guidelines, which address medical efficacy, should be considered before utilizing medical opinion in adjudication. Medical technology is constantly evolving, and we reserve the right to review and update Clinical UM Guidelines periodically. Clinical UM guidelines are used when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether or not to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the back of the member's card.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.